PGT-M Inconclusive Results: What Families Should Ask Before Embryo Transfer

Ask whether the known familial variant has been verified and whether the laboratory's assay was designed for that precise condition. PGT-M workflows may use additional linked genetic markers to reduce misinterpretation, and the ability to interpret an embryo can be affected by available family samples or technical limitations. The clinician should distinguish a true 'no-call' from a report that shows a result the patient finds confusing. The separate question of whether PGT-A was performed should also be clear; PGT-M and chromosome screening are different tests with different targets and limitations.

Embryo testing often examines a small biopsy rather than every cell of the embryo. Amplification or analysis may not provide a sufficiently reliable result for the intended variant, and laboratories differ in methods and reporting conventions. An inconclusive result should not be relabelled 'normal' simply because the embryo's appearance is good, nor assumed 'affected' because a test did not resolve. Request the actual wording, laboratory limitations and whether another independent analysis is technically possible or advisable. These are individual decisions because handling embryos again can introduce additional processes and burdens.

Discuss what repeating an assay would involve, whether warming and further biopsy are required, and what evidence exists about the possible effects of additional handling. A genetic counsellor can explain the residual risk, alternative reproductive choices and appropriate prenatal diagnostic pathways if pregnancy occurs. PGT is not equivalent to an absolute guarantee against genetic disease. The ethical and legal context for embryo selection also matters; ask that consent forms accurately reflect the specific inherited condition, laboratory practice and applicable Indian regulations rather than a generic testing sales brochure.

Different families may reasonably prioritise avoiding a particular inherited disorder, preserving embryo opportunities, limiting further procedures or seeking another genetics opinion. Age, number of available embryos and whether other embryos have clear results can change the discussion. For some cases, no additional embryo testing may be chosen; for others, an expert laboratory consultation could be decisive. Ask for written notes of the options and uncertainties, including what the result can and cannot exclude. The fertility specialist and genetics team should make a joint recommendation rather than relying on a single ambiguous label.

HomeIVF describes a doctor-led, home-supported fertility care approach, not a technique for performing IVF in a bedroom or from a mail-order kit. Where actually available, teleconsultation, selected clinician-ordered blood collection and appropriately supervised injection support may reduce unnecessary clinic travel. The treating team still decides when ultrasound imaging or in-person assessment is essential. Egg retrieval, embryology, sperm and egg handling, embryo freezing and embryo transfer stay in suitable licensed or registered facilities. Remote report review may be a sensible first step, but biopsy, embryo handling and transfer remain specialist laboratory and facility procedures. Before paying, ask which services are actually offered at your location, who provides them, where procedures take place, and whom you contact if symptoms require urgent assessment.

A useful consultation should end with decisions, not a generic promise. Bring original family genetic reports, PGT-M assay plan, embryo report and consent documents. Ask the clinician to explain what exact uncertainty made the result inconclusive and whether additional testing, counselling or prenatal diagnosis would affect the decision. Clarify the treatment choices if the first plan does not work, which finding would change the recommendation, and the point at which another specialist should be involved. If a test or add-on is suggested, request its purpose, limitations and out-of-pocket price. Consent should cover medicines, sample handling, facility procedures and the communication plan. It is reasonable to request a written summary; a second opinion can be valuable when results and recommendations do not seem to match.

Example decision, not a prediction: A family has one embryo with a clear PGT-M report and another marked 'no-call'. They request the laboratory method and meet a genetic counsellor before deciding if repeat testing or a different reproductive choice is proportionate. The final plan explicitly records residual uncertainty. The next step is to compare the available evidence, personal circumstances and practical constraints with a qualified clinician. Two people asking about the same headline condition may receive different recommendations because age, prior history, laboratory findings and safety needs are different. No blood test, embryo label or quoted package can guarantee a live birth. This example is for understanding the questions, not for self-prescribing medication or skipping clinical review.